Amanda Weber

Amanda Weber

Auto-generated profile, based on publicly available information

Amanda Weber

Departments of Neurology and

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Pediatric Neurology
Verified
Journal Article
Closed access
AWAmanda Weber
Amanda Weber
JCJustin Cole
Justin Cole
JMJohn R. Mytinger
John R. Mytinger

1 February 2016 in Pediatric Neurology
Verified
Journal Article
Closed access
DADara V. Albert
Dara V. Albert
CPCharles P. Pluto
Charles P. Pluto
AWAmanda Weber
Amanda Weber
JVJorge Vidaurre
Jorge Vidaurre
FBFatima Barbar-Smiley
Fatima Barbar-Smiley
BMBethanie Morgan-Followell
Bethanie Morgan-Followell

1 March 2015 in Epileptic Disorders
Verified
Journal Article
Closed access
PDF file
JMJohn R Mytinger
John R Mytinger
AWAmanda Weber
Amanda Weber
GHGeoffrey L Heyer
Geoffrey L Heyer
Although adrenocorticotropic hormone is the most commonly used treatment for infantile spasms in the United States, the optimal regimen for this indication is not known. The purpose of this study was to elucidate the optimal adrenocorticotropic hormone treatment duration. We conducted a retrospective chart review of response to adrenocorticotropic hormone among all patients with infantile spasms managed at our institution from January 2009 to September 2013. Treatment response was defined as clinical remission for greater than or equal to 28 days starting at any point within the adrenocorticotropic hormone course and remission of hypsarrhythmia (or definite EEG improvement if hypsarrhythmia was absent at baseline). For responders, the diagnostic and post‐treatment EEG tracings were reviewed. Electroclinical remission was achieved in 21 of 39 patients (54%) receiving adrenocorticotropic hormone, including 11/25 (44%) receiving a long course (typically 12 weeks) and 10/14 (71%) receiving a short course (typically four weeks). The mean time to clinical remission was 5.8 days (median: 5 days; range: 1–20 days). Only one patient responded beyond two weeks of treatment. This study provides Class IV evidence that among patients with infantile spasms, the response to adrenocorticotropic hormone is most often determined early in the treatment course. Given the importance of rapid remission, clinicians should consider adding or changing treatment if infantile spasms do not resolve within two weeks of adrenocorticotropic hormone initiation. Further study is needed to determine the optimal adrenocorticotropic hormone regimen for infantile spasms.

1 March 2018 in Journal Of Clinical Neurophysiology
Verified
Journal Article
Closed access
JMJohn R. Mytinger
John R. Mytinger
AWAmanda Weber
Amanda Weber
JVJorge Vidaurre
Jorge Vidaurre
Purpose: To assess for the presence of high amplitude EEG background slow waves in normal young children. Methods: One hundred children with normal development ages 3 to 18 months had normal EEGs for spells and did not have seizures or epilepsy. Three electroencephalographers retrospectively reviewed 5 minutes of stable stage II sleep to measure background slow waves for peak-to-peak amplitudes. A standard 10-20 longitudinal bipolar montage was used. Interrater agreement was assessed by intraclass correlation coefficient. Results: Interrater agreement between reviewers in the assessment of recurrent slow wave amplitudes was excellent (intraclass correlation coefficient = 0.97). Slow wave amplitudes were the highest in the posterior head regions for all patients. We found recurring slow waves of 500 µV in 17%, 49%, 30%, 3% and 1%, respectively. Conclusions: Although hypsarhythmia typically includes high amplitude background slow waves of >200 or >300 µV, we found that 83% and 34% of normal children had recurring posterior background slow waves of >200 or >300 µV, respectively. These data may be useful in the EEG background assessment of young children, for determining the presence or absence of hypsarhythmia, and determining treatment response in children with epileptic spasms.